The latest business news around the world. Written by Market Business News's very own editorial team to deliver reliable, up to date, and honest news.

Baxter International, Inc. – Company Information

0
Baxter logo
Company Baxter International, Inc.
Headquarters One Baxter Parkway, Deerfield, IL 60015, USA
Chairman and CEO Robert L. Parkinson, Jr.
CFO Robert J. Hombach
Industry Medical Equipment
Founder Dr. Donald Baxter
Founded 1931
Type Public
NYSE stock symbol BAX
Revenue $16.671 billion (2014)
Net income $2,497 million (2014)
Earnings per share $3.56 USD (2014)
Employees 66,000 (2014)
Website http://www.baxter.com/
Investor relations contact number: 222-948-3371

Baxter International, Inc. an American health care company, based in Deerfield, Illinois.

The company is involved in the development, manufacturing and marketing of products for patients with infectious diseases, immune disorders, hemophilia, trauma, kidney disease, and other chronic and acute medical conditions.

Its business operations are comprised of two main areas:

BioScience: this segment focuses on immunoglobulin therapies, critical care therapy, pulmonology therapy, regenerative medicine and biosurgery, hemophilia therapy, and vaccines.

Medical Products: this segment represents a little more than half of Baxter’s annual sales. It includes intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, IV nutrition products, infusion pumps and inhalation anesthetics.

It manufactures its products in 30 countries and sells them in over 100 countries.

The company was founded by Donald Baxter in 1931 and incorporated under Delaware law.The business originally manufactured and distributed intravenous therapy solutions.

Baxter International became globally well known after producing the first functioning artificial kidney in 1956.

In 2011 Baxter acquired the medical device company Baxa.


Income statement data (in $ millions) 2014* 2013*
Net sales $16,671 $14,967
Cost of sales $8,514 $7,495
Gross margin $8,157 $7,472
Marketing and administrative expenses $4,029 $3,642
Research and development expenses $1,421 $1,165
Income before income taxes $2,439 $2,546
Income tax expense $493 $534
Net income $2,497 $2,012
Comprehensive income $823 $2,846
Balance sheet data (in $ millions)
Total assets $25,917 $25,224
Long-term debt and lease obligations $7,606 $8,126
Total Baxter International Inc. shareholders’ equity $8,120 $8,463
Common share data (in $)
Earnings per Common Share – Basic $3.59 $3.70
Earnings per Common Share – Diluted $3.56 $3.66
Cash flow data (in $ millions)
Cash flows from operations $3,215 $3,198
Cash flows from investing activities $(1,542) $(5,362)
Cash flows from financing activities $(1,402) $1,645
Cash and equivalents at beginning of period $2,733 $3,270
Cash and equivalents at end of period $2,925 $2,733

*Years Ended December 31
Source: “Baxter International, Inc. Form 10-K 2014”